Prodrugs of anticancer agents

Advanced Drug Delivery Reviews

Volumn 19, Issue 2, 1996, Pages 241-273

  Sinhababu, Achintya K ^b   Thakker, Dhiren R ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Acid phosphatase; Antibody directed enzyme prodrug therapy (ADEPT); Anticancer agent; Azoreductase; CNS delivery; Hypoxia selectivity; N Oxide; Nitroaromatic; Nitroimidazole; Plasmin; Prodrug; Quinone; Taxol; Tumor targeting; Glucuronidase; Glutamyl transpeptidase

Indexed keywords

AGENTS; ANTIGENS; CELLS; DNA; DRUG THERAPY; ENZYMES; ONCOLOGY; PHARMACOKINETICS; SOLUBILITY; TISSUE; TOXICITY; TRANSPORT PROPERTIES;

ANTICANCER AGENTS; ANTITUMOR ACTIVITY; CANCER CHEMOTHERAPY; CYTOTOXIC AGENTS; DNA REPLICATION; HYPOXIA SELECTIVITY; PLASMIN; PRODRUGS; QUINONE; TUMOR TARGETING;

DRUG PRODUCTS;

1,4 BENZOQUINONE; ACID PHOSPHATASE; ANTINEOPLASTIC AGENT; AROMATIC NITRO COMPOUND; AZO REDUCTASE; BISANTRENE; BUTYRIC ACID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; GLUCURONIDE; NITROIMIDAZOLE; PACLITAXEL; PLASMIN; PRODRUG; QUINONE DERIVATIVE; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; CELL DIVISION; CYTOTOXICITY; DNA REPAIR; DNA REPLICATION; DRUG DESIGN; DRUG SOLUBILITY; DRUG TARGETING; DRUG TRANSPORT; HYPOXIA; PRIORITY JOURNAL; REVIEW;

EID: 0343337640     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00109-K     Document Type: Review

References (235)

1. Foye, W.O. (1995) Cancer Chemotherapeutic Agents, American Chemical Society, Washington, DC.
2. Hellmann, K. and Carter, S.K. (1987) Fundamentals of Cancer Chemotherapy, McGraw-Hill, New York.
3. Wooley, P.V. (1989) Cancer Management in Man: Biological Response Modifiers, Chemotherapy, Antibiotics, Hyperthermia, Supporting Measures, Academic Press, New York.
4. Albert, A. (1958) Chemical aspects of selective toxicity. Nature 182, 421-423
5. Harper, N.J. (1959) Drug latentiation. J. Med. Pharm. Chem. 1, 467-500.
6. Connors, T.A. (1985) Prodrugs in cancer chemotherapy. In: H. Bundgaard (Ed.), Design of Prodrugs, Elsevier, Amsterdam, pp. 291-316.
7. Zee-Chang, R.K.-Y. and Cheng, C.C. (1989) Delivery of anticancer drugs. Methods Find. Exp. Clin. Pharmacol. 11, 439-529.
8. Alexander, P. and Holy, A. (1994) Prodrugs of analogs of nucleic acid components. Coll. Czech. Chem. Commun. 59, 2127-2165.
9. Jones, R.J. and Bischofberger, N. (1995) Minireview: nucleotide prodrugs. Antiviral Res. 27, 1-17.
10. Hasegawa, T. and Kawaguchi, T. (1994) Future of prodrugs in antiviral therapy. Clin. Pharmacokinet. 27, 331-336.
11. Beauchamp, L.M. and Krenitsky, T.A. (1993) Acyclovir prodrugs: the road to valaciclovir. Drugs Future 18, 619-628.
12. Boyd, M.R., Safrin, S. and Kern, E.R. (1993) Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem. Chemother. 4, 3-11.
13. Bagshawe, K.D., Springer, C.J., Searle, F., Antoniw, P., Melton, R.G. and Herwood, R.F. (1988) A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 58, 700-703.
14. Sedlacek, H.-H., Seemann, G., Hoffman, D., Czech, J., Lorenz, P., Kolar, C. and Bosslet, K. (1992) Antibodies as Carriers of Cytotoxicity (Contributions to Oncology Vol. 43), Karger, Basel, pp. 114-208.
15. Jungheim, L.N. and Shepard, T.A. (1994) Design of antitumor prodrugs: substrates for antibody targeted enzymes. Chem. Rev. 94, 1553-1566.
16. Bagshawe, K.D. (1994) Antibody-directed enzyme prodrug therapy. Clin. Parmacokinet. 27, 368-376.
17. Bagshawe, K.D. (1994) Antibody-directed enzyme prodrug therapy (Adept). J. Control. Release 28, 187-193.
18. Huber, B.E., Richards, C.A. and Austin, E.A. (1994) Virus-directed enzyme/prodrug therapy (VDEPT) selectively engineering drug sensitivity into tumors. Ann. N.Y. Acad. Sci. 7, 104-114.
19. Wallace, P.M. and Senter, P.D. (1994) Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Methods Find. Exp. Clin. Pharmacol. 16, 505-512.
20. Huennekens, F.M. (1994) Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates. Trends Biotechnol. 2, 234-239.
21. Bagshawe, K.D. (1993) Antibody-directed enzyme prodrug therapy (ADEPT). Adv. Pharmacol. 24, 99-121.
22. Knox, R.J., Friedlos, F. and Boland, M.P. (1993) The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev. 12, 195-212.
23. Bosslet, K., Czech, J., Lorenz, P., Sedlacek, H.H., Schuermann, M. and Seemann, G. (1993) Molecular and functional characterization of a fusion protein suited for tumour specific prodrug activation. In: Epenetos, A.A. (Ed.), Monoclonal Antibodies 2: Applications in Clinical Oncology, Chapman and Hall, London, pp. 205-217.
24. Senter, P.D. and Wallace, P.M. (1993) Monoclonal antibody enzyme conjugates for prodrug activation: therapeutic effects and mechanistic considerations. In: Epenetos, A.A. (Ed.), Monoclonal Antibodies 2: Applications in Clinical Oncology, Chapman and Hall, London, pp. 453-461.
25. Senter, P.D., Wallace, P.M., Svensson, H.P., Vrudhula, V.M., Kerr, D.E., Hellstrom, I. and Hellstrom, K.E. (1993) Generation of cytotoxic agents by targeted enzymes. Bioconj. Chem. 4, 3-9.
26. Blakey, D.C. (1992) Drug targeting with monoclonal antibodies. Rev. Oncol. 5, 91-97.
27. Senter, P.D., Wallace, P.M., Svensson, H.P., Kerr, D.E., Hellstrom, I. and Hellstrom, K.E. (1991) Activation of prodrugs by antibody-enzyme conjugates. Adv. Exp. Med. Biol. 303, 97-105.
28. Springer, C.J. and Niculescu-Duvaz, I. (1995) Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Anticancer Drug Des. 10, 361-372.
29. Bagshawe, K.D., Rogers, G.T., Sharma, S.K., Antoniw, P., Sherwood, R., Springer, C., Searle, F., Burke, P., Melton, R., Boden, J. and Green, A. (1990) Antibody-directed enzyme prodrug therapy (ADEPT). In: Baldwin, R.W., Byers, V.S. and Mann, R.D. (Eds), Monoclonal Antibodies and Immunoconjugates, Parthenon, NJ, pp. 95-102.
30. Senter, P.D. (1990) Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J. 4, 188-193.
31. Senter, P.D. (1990) Antitumor effects of antibody enzyme conjugates in combination with prodrugs. Front. Radiat. Ther. Oncol. 24, 132-141.
32. Bagshawe, K.D. (1987) Antibody directed enzyme revive anti-cancer prodrugs concept. Br. J. Cancer 56, 531-532.
33. Eccles, S.A., Court, W.J., Box, G.A., Dean, C.J., Melton, R.G. and Springer, C.J. (1994) Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res. 54, 5171-5177.
34. Springer, C.J., Niculescu-Duvaz, I. and Pedley, B. (1994) Novel prodrugs of alkylating agents derived from 2-fluoro-and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. J. Med. Chem. 37, 2361-2370.
35. Sharma, S.K., Bagshawe, K.D., Burke, P.J., Boden, J.A., Rogers, G.T., Springer, C.J., Melton, R.G. and Sherwood, R.F. (1994) Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. Cancer 73 (Suppl. 3), 1114-1120.
36. Sharma, S.K., Boden, J.A., Springer, C.J., Burke, P.J. and Bagshawe, K.D. (1994) Antibody-directed enzyme prodrug therapy (ADEPT). Cell Biophys. 24/25, 219-228.
37. Springer, C.J., Poon, G.K., Sharma, S.K. and Bagshawe, K.D. (1993) Identification of prodrug, active drug, and metabolites in an ADEPT clinical study. Cell Biophys. 2, 9-26.
38. Blakey, D.C., Valcaccia, B.E., East, S., Wright, A.F., Boyle, F.T., Springer, C.J., Burke, P.J., Melton, R.G. and Bagshawe, K.D. (1993) Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophys. 22, 1-8.
39. 2. J. Immunol. Methods 158, 49-56.
40. Springer, C.J., Antoniw, P., Bagshawe, K.D. and Wilman, D.E.V. (1991) Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anti-Cancer Drug Des. 6, 467-479.
41. Sharma, S.K., Bagshawe, K.D., Springer, C.J., Burke, P.J., Rogers, G.T., Boden, J.A., Antoniw, P., Melton, R.G. and Sherwood, R.F. (1991) Antibody directed enzyme prodrug therapy (ADEPT): a three phase system. Dis. Markers 9, 225-231.
42. Bagshawe, K.D., Sharma, S.K., Springer, C.J., Antoniw, P., Boden, J.A., Rogers, G.T., Burke, P.J., Melton, R.G. and Sherwood, R.F. (1991) Antibody directed enzyme prodrug therapy (ADEPT): clinical report. Dis. Markers 9, 233-238.
43. Springer, C.J., Bagshawe, K.D., Sharma, S.K., Searle, F., Boden, J.A., Antoniw, P., Burke, P.J., Rogers, G.T., Sherwood, R.F. and Melton, R.G. (1991) Ablation of human cariocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J. Cancer 27, 1361-1366.
44. Bagshawe, K.D., Sharma, S.K., Springer, C.J., Antoniw, P., Rogers, G.T., Burke, P.J., Melton, R. and Sherwood, R. (1991) Antibody-enzyme conjugates can generate cytotoxic drugs from inactive precursors at tumor sites. Antibody Immunoconj. Radiopharm. 4, 915-922.
45. Springer, C.J., Antoniw, P., Bagshawe, K.D., Searle, F., Bisset, G.M.F. and Jarman, M. (1990) Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. 33, 677-681.
46. Vyas, D.M. (1994) Phosphatase activated water-soluble prodrugs of taxol. Abstr. Pap. Am. Chem. Soc. Med. Abstr. No. 142.
47. Haisma, H.J., Boven, E., Van Muijen, M., De Vries, R. and Pinedo, H.M. (1992) Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphates for specific activation of the prodrug etoposide phosphate. Cancer Immunol. Immunother. 34, 343-348.
48. Wallace, P.M. and Senter, P.D. (1991) In vitro, in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconj. Chem. 2, 349-352.
49. Sahin, U., Hartmann, F., Senter, P., Pohl, C., Engert, A., Diehl, V. and Pfreundschuh, M. (1990) Specific activation of the prodrug mitomycin phosphate by a bispecific anti-cd30/anti-alkaline phosphatase monoclonal antibody. Cancer Res. 50, 6944-6948.
50. Senter, P.D., Schreiber, G.J., Hirschberg, D.L., Ashe, S.A., Hellstrom, K.E. and Hellstrom, I. (1989) Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res. 49, 5789-5792.
51. Senter, P.D., Saulnier, M.G., Schreiber, G.J., Hirschberg, D.L., Brown, J.P., Hellstrom, I. and Hellstrom, K.E. (1988) Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA 85, 4842-4846.
52. Haisma, H.J., Van Muijen, M., Pinedo, H.M. and Boven, E. (1994) Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-β-glucuronidase conjugate in the specific treatment of cancer. Cell Biophys. 24/25, 185-192.
53. Bosslet, K., Czech, J. and Hoffmann, D. (1994) Tumor selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 54, 2151-2159.
54. Vingerhoeds, M.H., Haisma, H.J., Van Muijen, M., Van de Rijt, R.B.J., Crommelin, D.J.A. and Storm, G. (1993) A new application for liposomes in cancer therapy. FEBS Lett. 336, 485-490.
55. Wang, S.-M., Chern, J.-W., Yeh, M.-Y., Ng, J.C., Tung, E. and Roffler, S.R. (1992) Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res. 52, 4484-4491.
56. Bosslet, K., Czech, J., Lorenz, P., Sedlacek, H.H., Schuermann, M. and Seemann, G. (1992) Molecular and functional characterisation of a fusion protein suited for tumor specific prodrug activation. Br. J. Cancer 65, 234-238.
57. Haisma, H.J., Boven, E., Van Muijen, M., De Jong, J., Van der Vijgh, W.J.F. and Pined H.M. (1992) A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br. J. Cancer 66, 474-478.
58. Roffler, S. (1991) Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem. Pharmacol. 42, 2062-2065.
59. HER2 Fv-β-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 55, 63-70.
60. Svensson, H.P., Wallace, P.M. and Senter, P.D. (1994) Synthesis and characterization of monoclonal antibody-β-lactamase conjugates. Bioconj. Chem. 5, 262-267.
61. Jungheim, L.N., Shepherd, T.A. and King, J.K. (1993) Synthesis of a cephalosporin-doxorubicin antitumor prodrug: a substrate for an antibody-targeted enzyme. Heterocycles 35, 339-347.
62. Meyer, D.L., Jungheim, L.N., Law, K.L., Mikolajczyk, S.D., Shepherd, T.A., Mackensen, D.G., Briggs, S.L. and Starling, J.J. (1993) Site-specific prodrug activation by antibody-β-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res. 53, 3956-3963.
63. Goshorn, S.C., Svensson, H.P., Kerr, D.E., Somerville, J.E., Senter, P.D and Fell, H.P. (1993) Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to β-lactamase. Cancer Res. 53, 2123-2127.
64. Hanessian, S. and Wang, J. (1993) Design and sythesis of a cephalosporin-carboplatinum prodrug activatable by a β-lactamase. Can. J. Chem. 71, 896-906.
65. Vrudhula, V.M., Svensson, H.P., Kennedy, K.A., Senter, P.D. and Wallace, P.M. (1993) Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-β-lactamase conjugates. Bioconj. Chem. 4, 334-340.
66. Svensson, H.P., Kadow, J.F., Vrudhula, V.M., Wallace, P.M. and Senter, P.D. (1992) Monoclonal antibody-β-lactamase conjugates for the activities of a cephalosporin mustard prodrug. Bioconj. Chem. 3, 176-181.
67. Goldenberg, D.M., Blumenthal, R.D. and Sharkey, R.M. (1993) Radioimmunoconjugates in cancer therapy. Proc. Am. Assoc. Cancer Res. 34, 623-624.
68. Jungheim, L.N., Shepherd, T.A. and Meyer, D.L. (1992) Synthesis of acylhydrazido-substituted cephems, design of cephalosporin-vinca alkaloid prodrugs: substrates for an antibody-targeted enzyme. J. Org. Chem. 57, 2334-2340.
69. Meyer, D.L., Jungheim, L.N., Mikolajczyk, S.D., Shepherd, T.A., Starling. J.J. and Ahlem, C.N. (1992) Preparation and characterization of a β-lactamase-fab′ conjugate for the site specific activation of oncolytic agents. Bioconj. Chem. 3, 42-48.
70. Shepherd, T.A., Jungheim, L.N., Meyer, D.L. and Starling, J.J. (1991) A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody β-lactamase conjugate for the treatment of cancer. Bioorg. Med. Chem. Lett. 1, 21-26.
71. Haenseler, E., Esswein, A., Vitols, K.S., Montejano, Y., Mueller, B.M., Reisfeld, R.A. and Huennekens, F.M. (1992) Activation of methotrexate-α-alanine by carboxypeptidase A-monoclonal antibody conjugate. Biochemistry 31, 891-897.
72. Vitols, K.S., Haenseler, E., Montejano, Y., Baer, T. and Huennekens, F.M. (1992) Activation of methotrexate prodrugs by enzyme/monoclonal antibody conjugates. Pteridines 3, 125-126.
73. Harris, J.D., Gutierrez, A.A., Hurst, H.C., Sikora, K. and Lemoine, N.R. (1994) Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther. 1, 170-175.
74. Senter, P.D., Su, P.C.D., Katsuragi, T., Sakai, T., Cosand, W.L., Hellstrom, I. and Hellstrom, K.E. (1991) Generation of 5-fluorocytosine by monoclonal antibody cytosine deaminase conjugates. Bioconj. Chem. 2, 447-451.
75. Gesson, J.-P., Jacquesy, J.-C., Mondon, M., Petit, P., Renoux, B., Andrianomenjanahary, S., Van, H.D.-T., Koch, M., Michel, S., Tillequin, F., Florent, J.-C., Monneret, C., Bosslet, K., Czech, J. and Hoffmann, D. (1994) Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates. Anti-Cancer Drug Des. 9, 409-423.
76. Mauger, A.B., Burke, P.J., Somani, H.H., Friedlos, F. and Knox, R.J. (1994) Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J. Med. Chem. 37, 3452-3458.
77. Bignami, G.S., Senter, P.D., Grothaus. P.G., Fischer, K.J., Humphreys, T. and Wallace, P.M. (1992) N-(4′-hydroxyphenylacetyl) palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate. Cancer Res. 52, 5759-5764.
78. Kerr, D.E., Senter, P.D., Burnett, W.V., Hirschberg, D.L., Hellstrom, I and Hellstrom, K.E. (1990) Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol. Immunother. 31, 202-206.
79. Vrudhula, V.M., Senter, P.D., Fischer, K.J. and Wallace, P.M. (1993) Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate. J. Med. Chem. 36, 919-923.
80. Borrebaeck, C.A.K., Danielsson, L., Ohlin, M., Carlsson, J. and Carlsson, R. (1990) In: Borrebaeck, C.A.K. and Larrick, J.W. (Eds), Therapeutic Monoclonal Antibodies, Stockton Press, Houndmills, pp. 1-15.
81. Shokat, K.M., Leumann, C.J., Sugasawara, R. and Schultz, P.G. (1989) A new strategy for the generation of catalytic antibodies. Nature 338, 269-274.
82. Mattes M.J. (1987) Biodistribution of antibodies after intra-peritoneal and intravenous injection and effect of carbohydrate modification. J. Natl. Cancer Inst. 79, 855-863.
83. Sharma, S.K., Bagshawe, K.D. Burke, P.J., Boden, R.W. and Rogers, G.T. (1990) Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br. J. Cancer 61 659-62.
84. Ong, C.L., Ettenson, D., Sharkey, R.M., Marks, A., Baumal, R., Goldenberg, D.M. and Mattes, M.J. (1991) Galactose-conjugated antibodies in cancer therapy: properties and principles of action. Cancer Res. 51, 1619-1626.
85. Brown, J.M. (1993) SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 67, 1163-1170.
86. Moulder, J.E. and Rockwell, S. (1987). Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev. 5, 313-341.
87. 2 tension measurements. Cancer Res. 51, 6098-6102.
88. Mueller-Klieser, W., Vaupel, P., Manz, R. and Schmidseder, R. (1981) Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int. J. Radiat. Oncol. Biol. Phys. 7, 1397-1404.
89. Vaupel, P., Schlenger, K., Knoop, C. and Hockel, M. (1991) Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized oxygen tension measurements. Cancer Res. 51 3316-3322.
90. Kennedy, K.A. (1987) Hypoxic cell as specified drug targets for chemotherapy. Anticancer Drug Des. 2, 181-194.
91. Sartorelli, A.C. (1988). Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res. 48, 775-778.
92. Tannock, I. and Guttman, P. (1981) Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br. J. Cancer 42, 245-248.
93. Lin, A.J., Cosby, L.A., Shansky, C.W. and Sartorelli, A.C. (1972) Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. J. Med. Chem. 15, 1247-1252.
94. Denny, W.A. (1995) Hypoxia-selective cytotoxins. In: Foye, W.O. (Ed.), Cancer Chemotherapeutic Agents, American Chemical Society, Washington, DC, pp. 483-497.
95. Kedderis, G.L. and Miwa, G.T. (1988) The metabolic activation of nitroheterocyclic therapeutic agents. Drug Metab. Rev. 19, 33-62.
96. Panicucci, R., Heal, R., Laderoute, K., Cowan, D.M.S., McClelland, R.A. and Rauth, A.M. (1989) NLP-1: a DNA intercalating hypoxic cell radiosensitizer and cytotoxin. Int. J. Radiat. Oncol. Biol. Phys. 16, 1039-1043.
97. Brendel, M. and Ruhland, A. (1984) Relationships between functionality and genetic toxicology of selected DNA-damaging agents. Mutat. Res. 133, 51-85.
98. Cowan, D.M.S., Panicucci, R., McClelland, R.A. and Rauth, A.M. (1991) Targeting radiosensitizers to DNA by attachment of an intercalating group: nitroimidazole-linked phenanthridines. Radiat Res. 127, 81-89.
99. Denny, W.A., Roberts, P.B., Anderson, R.F., Brown, J.M. and Wilson, W.R. (1992) LA-1: a 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. Int. J. Radiat. Oncol. Biol. Phys. 22, 553-556.
100. O'Neill, P., McNeil, S.S. and Jenkins, T.C. (1987) Induction of DNA crosslinks in vitro upon reduction of the nitroimidazole aziridines RSU-1069 and RSU 1131. Biochem. Pharmacol. 36, 1787-1792.
101. Adams, G.E., Ahmed, I., Sheldon, P.W. and Stratford, I.J. (1984) Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br. J. Cancer 40, 571-577.
102. Naylor, M.A., Stephens, M.A., Cole, S., Threadgill, M.D., Stratford, I.J., O'Neill, P., Fielden, E.M. and Adams, G.E. (1990) Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins. J. Med. Chem. 33, 2603-2610.
103. Hill, R.P., Guylas, S. and Whitmore, G.F. (1986) Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069. Br. J. Cancer 53, 743-751.
104. Naylor, M.A., Stephens, M.A., Stratford, I.J., Koehane, A., O'Neill, P., Threadgill, M.D., Webb, P., Fielden, E.M. and Adams, G.E. (1991) Aziridinyl nitropyrroles and nitropyrazoles as hypoxia-selective cytotoxins and radiosensitizers. Anti-Cancer Drug Des. 6, 151-167.
105. Threadgill, M.D., Webb, P., O'Neill, P., Naylor, M.A., Stephens, M.A., Stratford, I.J., Cole, S., Adams, G.E. and Fieldon, E.M. (1991) Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins. J. Med. Chem. 34, 2112-2120.
106. Jenkins, T.C., Naylor, M.A., O'Neill, P., Threadgill, M.D., Cole, S., Stratford, I.J., Adams, G.E., Fielden, E.M., Suto, M.J. and Stier, M.A. (1990) Synthesis and evaluation of α-[[(2-haloethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of α-[(1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (RS-U-1069) and its analogs which are radiosensitizers and bioreductively activated cytotoxins. J. Med. Chem. 33, 2603-2610.
107. Cole, S., Stratford, I.J., Bowler, J., Nolan, J., Wright, E.J., Lorimore, S.A. and Adams, G.E. (1991) Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice. Int. J. Radiat. Oncol. Biol. Phys. 21, 387-395.
108. Binger, M. and Workman, P.J. (1991) Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed function hypoxic cell sensitizer/cytotoxin α-(1-aziridinomethyl)-2-nitro-1H-imadazole-1 -ethanol (RSU 1069). Cancer Chemother. Pharmacol. 29, 37-47.
109. Bremner, J.CM. (1993) Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation. Cancer Metastasis Rev. 12, 177-193.
110. Prakash, S.R., Correa, I.D., Gan, L.-S., Chism, J.P., Arrendale, R.F., Miwa, G.T. and Thakker, D.T. (1995) Tumor targeting by reductive activation of nitroimidazole carbamates. In: Allen, J. and Voges, R. (Eds), Synthesis and Applications of Isotopically Labeled Compounds - 1994. Wiley, Chichester, pp. 573-576.
111. LoRusso, P., Wozniak, A.J., Polin, L., Capps, D., Leopold, W.R., Werbel, L.M., Biernat, L., Dan, M.A., Corbett, T.H. (1990) Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res. 50, 4900-4905.
112. Sebolt, J.S., Scavone, S.V., Pinter, C.D., Hamelehle, K.I., von Hoff, D.D. and Jackson, R.C. (1987) Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res. 47, 4299-4304.
113. Wilson, W.R., Denny, W.A., Twigden, S.J., Baguley, B.C. and Probert, J.C. (1984) Selective toxicity of nitracrine to hypoxic mammalian cells. Br. J. Cancer 49, 215-223.
114. Wilson, W.R., Anderson, R.F. and Denny, W.A. (1989) Hypoxia-selecive antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine. J. Med. Chem. 32, 23-30.
115. Wilson, W.R., Denny, W.A., Stewart, G.M., Fenn, A. and Probert, J.C. (1986) Reductive metabolism and hypoxia-selective toxicity of nitracrine. Int. J. Radiat. Oncol. Biol. Phys. 12, 1235-1238.
116. Wilson, W.R., Thompson, L.H., Anderson, R.F. and Denny, W.A. (1989) Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives. J. Med. Chem. 32, 31-38.
117. OConnor, C.J., Denny, W.A., McLennan, D.J., Sutton, B.M. and Wilson, W.R. (1991) Effect of reduction potential, on the rate of reduction of nitroacridines by xanthine oxidase and by dihydroflavin mononucleotide. J. Chem Soc. Perkin Trans. II. 951-954.
118. Denny, W.A. and Wilson, W.R. (1993) Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev. 12, 135-151.
119. Denny, W.A., Wilson, W.R., Atwell, G.J., Boyd, M., Pullen, S.M. and Anderson, R.F. (1990) Nitroacridines and nitroquinolines as DNA-affinic hypoxia-selective cytotoxins. In: Adams, G.E., Breccia, A., Wardman, P. and Fielden, E.M. (Eds), Activation of Drugs by Redox Processes (NATO Adv. Study Ser. Vol. 198), Plenum Press, New York, pp. 149-158.
120. Denny, W.A. and Wilson, W.R. (1986) Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J. Med. Chem. 29, 879-887.
121. Alston, T.A., Proter, D.J.T. and Bright, H.J. (1983) Enzyme inhibition by nitro and nitroso compounds. Acc. Chem. Res. 16, 418-424.
122. Lewis, D.F.V. (1989) Molecular orbital calculations on tumor-inhibitory aniline mustards: QSARs. Xenobiotica 19, 243-251.
123. Palmer, B.D., Wilson, W.R., Pullen, S.M. and Denny, W.A. (1990) Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines. J. Med. Chem. 33, 112-121.
124. Palmer, B.D., Wilson, W.R., Cliffe, S. and Denny, W.A. (1992) Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J. Med. Chem. 35, 3214-3222.
125. Firestone, A., Mulcahy, R.T. and Borch, R.F. (1991) Nitroheterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells. J. Med. Chem. 34, 2933-2935.
126. Denny, W.A., Wilson, W.R., Tercel, M., Van Zijl, P. and Pullen, S.M. (1994) Nitrobenzyl mustard quaternary salts: a new class of hypoxia-selective cytotoxins capable of releasing diffusible cytotoxins on bioreduction. Int. J. Radiat. Oncol. Biol. Phys. 29, 317-321
127. Atwell, G.J., Sykes, B.M., O'Connor, C.J. and Denny, W.A. (1994) Relationships between structure and kinetics of cyclization of 2-aminoaryl amides: potential prodrugs of cyclization-activated aromatic mustards. J. Med. Chem. 37, 371-380.
128. Keyes, S.R., Rockwell, S. and Sartorelli, A.C. (1985) Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. Cancer Res. 45, 3642-3645.
129. Rockwell, S., Keyes, S.R. and Sartorelli, A.C. (1988) Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumors by dicoumarol in vitro. Cancer Res. 48, 5471-5474.
130. Walton, M.I., Smith, P.J. and Workman, P. (1991) The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun. 3, 199-206.
131. Dulhanty, A.M. and Whitmore, G.F. (1991) Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT diaphorase. Cancer Res. 51, 1860-1865.
132. Carpino, L.A., Triolo, S.A. and Berglund, R.A. (1988) Reductive lactonization of strategically methylated quinone propionic acid esters and amides. J. Org. Chem. 54, 3303-3310.
133. Milstien, S. and Cohen, L.A. (1972) Stereopopulation control. I. Rate enhancement in the lactonizations of o-hydroxyhydrocinnamic acids. J. Am. Chem. Soc. 94, 9158-9165.
134. Borchardt, R.T. and Cohen, L.A. (1972) Stereopopulation control. II. Rate enhancement of intramolecular nucleophilic displacement. J. Am. Chem. Soc. 94, 9166-9174.
135. Borchardt, R.T. and Cohen, L.A. (1972) Stereopopulation control. III. Facilitation of intramolecular conjugate addition of the carboxyl group. J. Am. Chem. Soc. 94, 9175-9182.
136. Karle, J.M. and Karle, I.L. (1972) Correlation of reaction rate acceleration with rotational restriction. Crystal structure analysis of compounds with a trialkyl lock. J. Am. Chem. Soc. 94, 9182-9189.
137. Caswell, M. and Schmir, G.L. (1980) Formation and hydrolysis of lactones of phenolic acids. J. Am. Chem. Soc. 102, 4815-4821.
138. Amsberry, K.L. and Borchardt, R.T. (1991) Amine prodrugs which utilize hydroxy amide lactonization. I. A potential redox-sensitive amide prodrug. Pharm. Res. 8, 323-330.
139. Patterson, L.H. (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev. 12, 119-134.
140. White, I.N.H., Suzanger, M., Mattocks, A.R., Bailey, E., Farmer, P.B., Connors, T.A. (1989) Reduction of nitromin to nitrogen mustard: unscheduled DNA synthesis in aerobic or anaerobic rat hepatocytes, JB1, BL8 and Walker carcinoma cell lines. Carcinogenesis 10, 2113-2118.
141. Mann, J., Shervington, L.A. (1991) Synthesis of novel N-and S-mustards as potential pro-drugs activated by bioreductive processes. J. Chem. Soc. Perkin Trans. I 2961-2964.
142. Zeman, E.M., Brown, J.M., Lemmon, M.J., Hirst, V.K., Lee, W.W. (1986) SR 4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12, 1239-1242.
143. Fitzsimmons, S.A., Lewis, A.D. Riley, R.J. and Workman, P. (1994) Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 15, 1503-1510.
144. Lloyd, R.V., Duling, D.R., Rumyantseva, G.V., Mason, R.P. and Bridson, P.K. (1991). Microsomal reduction of 3-amino-1,2,4-benzotriazene 1,4-dioxide to a free radical. Mol. Pharmacol. 40, 440-445.
145. Suguira, M., Iwasaki, K. and Kato, R. (1976) Reduction of tertiary amine N-oxids by microsomal cytochrome P450. Mol. Pharmacol. 12, 322-334.
146. Cahill, A. and White, I.N.H. (1990) Reductive metabolism of 3-amino-1,2,4-benzotriazene-1,4-dioxide (SR4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines. Carcinogenesis 11, 1407-1411.
147. Baker, M.A., Zeman, E.M., Hirst, V.K. and Brown. J.M. (1988) Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cyjtotoxicity. Cancer Res. 48, 5947-5952.
148. Wang, J., Biedermann, K.A., Wolf, C.R. and Brown, J.M. (1993) Metabolism of the bioreductive cytotoxin SR 4233 by tumor cells: enzymatic studies. Br. J. Cancer 67, 321-325.
149. Costa, A.K., Baker, M.A., Brown, J.M. and Truddell, J.R. (1989) In vitro hepatotoxicity of SR 4233 (3-amino-1,2,4-benzotriazene-1,4-di-oxide), a hypoxic cytotoxin and potential antitumor agent. Cancer Res. 49, 925-929.
150. Kohane, A., Godden, J., Stratford, I.J. and Adams, G.E. (1990) The effects of three bioreductive drugs (mitomycin C, RSU 1069, and SR 4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation. Br. J. Cancer 61, 722-726.
151. Biederman, K.A., Wang, J. Graham, R.P. and Brown, J.M. (1991) SR4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br. J. Cancer 63, 358-362.
152. Stratford, I.J. and Stephens, M.A. (1989) The differntial hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int. J. Radiat. Oncol. Biol. Phys. 16, 973-976.
153. Naylor, M.A., Adams, G.E., Haigh, A., Cole, S. Jenner, T., Robertson, N, Siemann, D., Stephens, M.A. and Stratford, I.J. (1995) Fused pyrazine mono-N-oxides as bioreductive drugs III. Characterization of RB 90740 in vitro and in vivo. Anti-Cancer Drugs 6, 259-269.
154. Monge, A., Palop, J.A., de Cerain, A.L., Senador, V., Martinez-Crespo, F.J., Sainz, Y., Narro, S., Garcia, E., de Miguel, C., Gonzalez, M., Hamilton, E., Barker, A.J., Clarke, E.D. and Greenhow, D.T. (1995) Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides. J. Med Chem. 38, 1786-1792.
155. Workman and Double, J.A. (1978) Drug latentiation in cancer chemotherapy. Biomedicine 28, 2555-2562.
156. Greenstein, J.P. (1947) Biochemistry of Cancer, Chapter 8, Academic Press, New York.
157. Workman, P. (1978) Inhibition of human prostatic tumor acid phosphatase by N,N-p-di-2-chloroethylaminophenol, N,N-p-di-2-chloroethylaminophenyl phosphate and other difunctional nitrogen mustards. Chem-Biol. Interact. 20, 103-112.
158. Carl P., Chakravarty P.K., Katzenellenbogen J.A. and Weber M.J. (1980) Protease-activated prodrugs for cancer chemotherapy. Proc. Natl. Acad. Sci. 77, 2224-2228.
159. Manson M.M., Legg R.F., Watson J.V., Green J.A. and Neal G.E. (1981) An examination of the relative resistances to aflatoxin B1 and susceptibilities to gamma-glutamyltransferase negative and positive cell lines. Carcinogenesis 2, 661-670.
160. Wilman, D.E.V. (1986) Prodrugs in cancer chemotherapy. Biochem. Soc. Trans. 14, 375-382.
161. Connors, T.A. and Whisson, M.E. (1966) Cure of mice bearng advanced plasma cell tumours with aniline mustard: The relationship between glucuronidase activity and tumour sensitivity. Nature 210, 866-867.
162. Ross, W. C. J. and Warwick, G. P. (1955) Reduction of cytotoxic azo compounds by hydrazine and by the xanthine oxidase-xanthine system. Nature 176, 298-299.
163. Ross, W.C.J. and Warwick, G. P. (1956) Aryl-2-halogenoalkylamines. Part XVI. The preparation of 4-[di-(2-chloroalkyl)amino]azobenzenes. J. Chem. Soc. 1364-1369.
164. Bukhari, M.A., Connors, T.A., Gilsenan, A.M., Ross, W.C.J., Tisdale, M.J., Warwick, G.P. and Wilman, D.E.V. (1973) Cytotoxic agents designed to be selective for liver cancer. J. Natl. Cancer Inst. 50, 243-247.
165. Connors, T.A., Gilsenan, A. M., Ross, W. C. J., Bukhari, A., Tisdale, M. J. and Warwick, G. P. (1973) Agents designed specifically for the treatement of liver cancer. In: Garattini, S. and Franchi, G. (Eds), Chemotherapy of Cancer Dissemination and Metastasis, Raven Press, New York, pp. 367-376.
166. Kutscher, W. and Wolbergs, H. (1935) Prostataphosphatase. Z. Physiol. Chem. 236, 237-240.
167. Band, P.R., Banerjee, T.K., Patwardhan, V.C. and Eid, J.C. (1973) High-dose diethylstilbesterol therapy of prostate cancer after failure of standard doses of oestrogens. Cancer Med. Assoc. J. 109, 697-699.
168. Mittleman, A., Shukla, S.K., Welwaart, K. and Murphy, G.P. (1975) Oral estramustine phosphate (NSX-89199) in the treatment of advanced (stage D) carcinoma of the prostate. Cancer Chemother. Rep. 59, 219-223.
169. Double, J.A. and Workman, P.A. (1977) A new high-glucuronidase mouse tumour curable by aniline mustard therapy. Cancer Treat. Rep. 61, 909-911.
170. Connors, T.A., Farmer, P.B., Foster, A.B., Gilsenan, A.M., Jarman, M and Tisdale, M.J. (1973) Metabolism of aniline mustard [N,N-di-(2-chloroethyl)aniline]. Biochem. Pharmacol. 22, 1971-1980.
171. Young, C.W., Yogoda, A., Bitlar, E.S., Smith, S.W., Grabstald, H. and Whitmore, W. (1976) Therapeutic trial of aniline mustard in patients with advanced cancer. Comparison of therapeutic response with cytochemical assessment of tumor cell β-glucuronidase activity. Cancer 38, 1887-1895.
172. Peters, T.J., Seymour, C.A., Wells, G., Fakunle, F. and Neale, G. (1977) Gamma-glutamyltransferase levels in ascitic fluid and liver tissue from patients with primary hepatoma. Br. Med. J. Part I, 1576.
173. Prezioso, J.A., Hughey, R.P., Wang, N., Damodaran, K.M. and Bloomer, W.D. (1994) γ-Glutamyltranspeptidase expression regulates the growth-inhibitory activity of the anti-tumor prodrug γ-L-glutaminyl-4-hydroxy-3-iodobenzene. Int. J. Cancer 56, 874-879.
174. Chakravarty, P.K., Carl, P.L., Weber, M.J. and Katzenellenbogen, J.A. (1983) Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard. J. Med. Chem. 26. 633-638.
175. Chakravarty, P.K., Carl, P.L., Weber, M.J. and Katzenellenbogen, J.A. (1983) Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. J. Med. Chem. 26, 638-644.
176. Ashby, B.S. (1966) pH studies in human malignant tumours. Lancet 2, 312-315.
177. Voegtlin, C., Fitch, R.H., Kahler, H., Johnson, J.M. and Thomson, J.W. (1935) Experimental studies on cancer. I. The influence of patenteral administration of certain sugars on the pH of malignant tumours. Natl. Inst. Health Bull. 164, 1-14.
178. Gullino, P.M., Grantham, F.H. and Courtney, A.H. (1967) Glucose consumption by transplanted tumors in vivo. Cancer Res. 27, 1031-1040.
179. Jahde, E. and Rajewsky, M.F. (1982) Tumor-selective modification of cellular microenvironment in vivo: effect of glucose infusion on the pH in normal and malignant rat tissues. Cancer Res. 42, 1505-1512.
180. Suffness, M. (1993) Taxol: from discovery to therapeutic use. Ann. Rep. Med. Chem. 28, 305-314.
181. Deutsch, H.M., Hernandez, M., Haugwitz, R.D., Narayanan, V.L., Suffness, M. and Zalkow, L.H. (1989) Synthesis of congeners and prodrugs, 3. Water-soluble prodrugs of taxol with potent antitumor activity. J. Med. Chem. 32, 788-792.
182. Zhao, Z. and Kingston, D.G.I. (1991) Modified taxols, 6. preparation of water-soluble prodrugs of taxol. J. Natural Prod. 54, 1607-1611.
183. Mathew, A.E., Mejillano, M.R., Nath, J.P., Himes, R.H. and Stella, V.J. (1992) Synthesis and evaluation of some water soluble prodrugs and derivatives of taxol with antitumor activity. J. Med. Chem. 35, 145-151.
184. Nicolaou, K.C., Riemer, C., Kerr, M.A., Rideout, D. and Wrasidlo, W. (1993) Design, sythesis and biological activity of protaxols. Nature 364, 464-466.
185. Greenwald, R.B., Pendri, A., Bolikal, D. and Gilbert, C.W. (1994) Highly water soluble taxol derivatives: 2-polyethyleneglycol esters as potential prodrugs. Bioorg. Med. Chem. Lett. 4, 2465-2470.
186. Vyas, D.M., Wong, H., Crosswell, A.R., Casazza, A.M., Knipe, J.O., Mamber, S.W. and Doyle, T.W. (1993) Synthesis and antitumor evaluation of water slouble taxol phosphates. Bioorg. Med. Chem. Lett. 3, 1357-1360.
187. Ueda, Y., Mikkilineni, A.B., Knipe, J.O., Rose, W.C., Casazza, A.M. and Vyas, D.M. (1993) Novel water soluble phosphate prodrugs of taxol possessing in vivo antitumor activity. Bioorg. Med. Chem. Lett. 3, 1761-1766.
188. O'Dwyer, P.L., Leyland-Jones, B., Alonso, M.T., Marsoni, S. and Wittes, R.E. (1985) Etoposide (VP-16-213): current status of an active anticancer drug. N. Engl. J. Med. 312, 692-700.
189. Budman, D.R., Igwemezie, L.N., Kaul, S., Behr, J., Lichtman, S., Schulman, P., Vinciguerra, V., Allen, S.L., Kolitz, J., Hock, K., O'Neill, K., Schacter, L. and Barbhaiya, R.H. (1994) Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. J. Clin. Oncol. 12, 1902-1909.
190. Etoposide phosphate (BMY-4048-1). Investigator brochure on file with the Food and Drug Administration, Washington, DC, 1991.
191. Saulnier, M.G., Langley, D.R., Kadow, J.F., Senter, P.D., Knipe, J.O., Tun, M.M., Vyas, D.M. and Doyle, T.W. (1994) Sythesis of etoposide phosphate, bmy-40481: a water-soluble clinically active prodrug of etoposide. Bioorg. Med. Chem. Lett. 4, 2567-2572.
192. Rose, W.C., Basler, G.A., Trail, P.A., Saulnier, M., Crosswell, A.R. and Casazza, A.M. (1990) Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30. Invest. New Drugs 8, S25-S32.
193. Stella, V.J. and Kennedy, P.E. (1987) Water-soluble rapamycin prodrugs. US Patent No. 4,650803.
194. Supko, J.G. and Malspeis, L. (1994) Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. Cancer Chemother. Pharmacol. 33, 325-330.
195. Murdock, K.C., Lee, V.J., Citarella, R.V., Durr, F.E., Nicolau, G. and Kohlbrenner, M. (1993) N-Phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity. J. Med. Chem. 36, 2098-2101.
196. Pardridge, W.M., Oldendorf, W., Cancilla, P. and Frank, H. (1986) Blood-brain barrier: interface between medicine and the brain. Ann. Int. Med. 105, 82-95.
197. Rapoport, S.I. (1976) The Blood-Brain Barrier in Physiology and Medicine, Raven Press, New York.
198. Crone, C. (1986) The blood-brain barrier. A modified tight epithelium. In: Suckling, A.J., Rumsby, M.G. and Bradbury, M.W.B. (Eds), The Blood-Brain Barrier in Health and Disease. Ellis Harwood, Chichester, UK.
199. Stella, V.J., Charman, W.N.A. and Naringrekar, V.H. (1985) Prodrugs, do they have advantages in clinical practice? Drugs 29, 455-473.
200. Bodor, N. (1984) Novel approaches to the design of safer drugs: soft drugs and site-specific chemical delivery systems. Adv. Drug Res. 13, 225-331.
201. Bodor, N., El-Kommos, M.E. and Nath, C. (1986) In vivo elimination of dihydropyridine drug carriers from brain and blood of rats. Bull. Pharm. Sci. Assiut Univ. 9, 14-29.
202. Bodor, N., Farag, H. and Brewster, M. (1981) Site-specific, sustained release of drugs to the brain. Science 214, 1370-1372.
203. Bodor, N., Vasudevan, V.D.W., Estes, K. and Brewster, M.E. (1989) Improved delivery through biological membranes. XL1. Brain-enhanced delivery of chlorambucil. Int. J. Pharmacol. 53, 195-208.
204. Brewster, M.E. and Bodor, N.(1992) Redox approaches to drug delivery to the central nervous system. In: Frankenheim, J. and Brown, R.M. (Eds), Bioavailability of Drugs to the Brain and the Blood-Brain Barrier, US Department of Health and Human Services, Rockville, MD, pp. 169-201.
205. Nudelman, A., Ruse, M., Aviram, A., Rabizadeh, E., Shaklai, M., Zimrah, Y. and Rephaeli, A. (1992) Novel anticancer prodrugs of butyric acid. J. Med. Chem. 35, 687-694.
206. Chen, Z.-X. and Breitman, T.R. (1994) Tributyrin: a prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res. 54, 3494-3499.
207. Rabizadeh, E., Shaklai, M., Nudelman, A., Eisenbach, L. and Rephaeli, A. (1993) Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBS Lett. 328, 225-229.
208. Aviram, A., Zimrah, Y., Shaklai, M., Nudelman, A. and Rephaeli, A. (1994) Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an hl-60 leukemic cell line. Int. J. Cancer 56, 906-909.
209. Shealy, Y.F. (1995) Triazenylimidazoles, other triazenes, and imidazolo[5,1-d]-1,2,3,5-tetrazine-4(3H)-ones. In: Foye, W.O. (Ed.), Cancer Chemotherapeutic Agents, American Chemical Society, Washington, DC, pp. 159-186.
210. Struck, R.F., (1995) Nitrogen mustard and related structures. In: Foye, W.O. (Ed.), Cancer Chemotherapeutic Agents, American Chemical Society, Washington, DC, pp. 112-121.
211. Roberts, J.C., Franatio, D.J. and Zera, R.T. (1994) Chemoprotection against cyclophosphamide-induced urotoxicity: comparison of nine thiol protective agents. Anticancer Res. 14, 389-396, and references cited therein.
212. Niemeyer, U., Engel, J., Hilgard, P., Peukert, M., Pohl, J. and Sindermann, H. (1989) Mafosfamide - a derivative of 4-hydroxycyclophosphamide. Prog. Clin. Biochem. Med. 9, 35-60.
213. Tietze, L.F., Neumann, M., Mollers, T., Fischer, R., Glusenkamp, K.-H., Rajewsky, M.F. and Jahde, E. (1989) Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: a strategy for tumor-selective activation of cytocidal drugs. Cancer Res. 49, 4179-4184.
214. Tietze, L.F., Fischer, R., Beller, M. and Seele, R. (1990) Novel stable bioactivated cyclophosphamide derivatives for selective cancer chemotherapy, synthesis of aldophosphamide acetal-glycosides and their glycoconjugates. Liebigs Ann. Chem. 151-157.
215. Hadfield, A.F. and Sartorelli, A.C. (1984) The pharmacology of prodrugs of 5-fluorouracil and 1-β-D-arabinofuranosylcytosine. Adv. Pharmacol. Chemother. 20, 21-67.
216. Jones, G. (1985) Decreased toxicity and adverse reactions via prodrugs. In: Bundgaard, H. (Ed.), Design of Prodrugs, Elsevier, Amsterdam, pp. 199-241.
217. Wipf, P. and Li, W. (1994) Prodrugs of Ara-C. Drugs Future 19, 49-54.
218. Anantham, S. (1995) Fluoropyrimidines. In: Foye, W.O. (Ed.), Cancer Chemotherapeutic Agents, American Chemical Society, Washington, DC, pp. 49-58.
219. Ariyoshi, Y. (1994) Overview of new anticancer drugs developed in Japan. In: Kimura, K., Ota, K., Carter, S.K. and Friedmann T. (Eds), Cancer Chemotherapy: Challenges for the Future, Excerpta Medica, Amsterdam, pp. 157-217.
220. Au, J.L-S. and Sadee, W. (1980) Activation of Ftorafur [R,5-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and γ-butyrolactone. Cancer Res. 40, 2814-2819, and references cited therein.
221. Masquelier, M., Baurain, R. and Trouet, A. (1980) Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion. J. Med. Chem. 23, 1166-1170.
222. Baurain, R., Masquelier, M., Deprez-de Campeneere, D. and Trouet, A. (1980) Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo. J. Med. Chem. 23, 1171-1174.
223. Boven, E., Hendriks, H.R., Erkelens, C.A.M. and Pinedo, H.M. (1992) The anti-tumour effects of the prodrugs n-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts. Br. J. Cancer 66, 1044-1047.
224. Bennis, S., Garcia, C. and Robert, J. (1993) Aspects of the cellular pharmacology of N-l-leucyldoxorubicin in human tumor cell lines. Biochem. Pharmacol. 45, 1929-1931.
225. Jong, J.D., Vermerken, J.B. and Van Der Vijgh, W.J.F. (1992) Analysis and pharmacokinetics of a new prodrug N-l-leucyldoxorubicin and its metabolites inplasma using HPLC with fluorescence detection. J. Pharm. Biomed. Anal. 10, 309-314.
226. Canal, P., Roberts, J., Ramon, M., Baurain, R., Tresca, P., de Forni, M., Marty, M., Pujade-Lauraine, E., Bugat, R., Magis, A. and Belopmme, D. (1992) Human pharmacokinetics of N-l-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities. Clin. Pharmacol. Ther. 51, 249-259.
227. de Jong, J., Geijssen, G.J., Munniksma, C.N., Vermorken, J.B. and Van der Vijgh, W.J.F. (1992) Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. J. Clin. Oncol. 10, 1897-1906.
228. King, H.D., DeVirgilio, M.K., Martin, J.D., Radcliffe, R.D. and Coughlin, D.J. (1990) Synthesis and proteolytic cleavage of 3′-N-peptidyl-adriamycin prodrugs. In: Rivier, J.E. and Marshall, G.R. (Eds), Peptides - Chemistry, Structure and Biology, ESCOM, Leiden, pp. 137-139.
229. Yoon, E.J., Lee, E.D., Yoon, W.H., Shim, H.J., Lee, S.D., Kim, W.B., Yang, J. and Lee, M.G. (1994) Pharmacokinetics, tissue distribution, and biliary excretion of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM to dogs. A new adriamycin analog containing fluorine. Int. J. Pharm. 109, 181-187.
230. Shim, H.J., Lee, E.D., Yoon, E.J., Lee, S.D., Kim, W.B., Yang, J. and Lee, M.G. (1994) Pharmacokinetics of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM to rats. A new adriamycin analog containing fluorine. Int. J. Pharm. 103, 147-154.
231. Charman, W.N. and Stella, V.J. (1992) Lymphatic Transport of Drugs, CRC Press, Boca Raton, FL.
232. Stella, V.J. and Pochopin, N.L. (1992) Lipophilic prodrugs and the promotion of intestinal lymphatic drug transport. In: Charman, W.N. and Stella, V.J. (Eds), Lymphatic Transport of Drugs, CRC Press, Boca Raton, FL, pp. 181-210.
233. Wall, M.F., Abernathy, G.S., Carroll, F.L. and Taylor, D.J. (1969) The effects of some steroidal alkylating agents on experimental animal mammary tumor and leukemia systems. J. Med. Chem. 12, 810-818.
234. Garzon-Aburbeh, A., Pouapaert, J.H., Claesen, M., Dumont, P. and Atassi, G. (1983) 1,3-Dipalmitoylglycerol ester of chlorambucil as a lymphotropic, orally administrable antineoplastic agent. J. Med. Chem. 26, 1200-1203.
235. Deverre, J.R., Letourneux, Y, Couvreur, P. and Benoit, J.P. (1991) 1,3-Dipalmitoyl-(4-bis(2-chloroethyl)amino)-phenylalaninoyl) a stable and lymphotropic prodrug of melphalan. Proc. Int. Symp. Control. Release Bioact. Mater. 18, 215-216.